Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Research & Development: 2011-2024

Historic Research & Development for Agios Pharmaceuticals (AGIO) over the last 14 years, with Dec 2024 value amounting to $301.3 million.

  • Agios Pharmaceuticals' Research & Development rose 19.79% to $86.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $334.3 million, marking a year-over-year increase of 12.95%. This contributed to the annual value of $301.3 million for FY2024, which is 1.95% up from last year.
  • According to the latest figures from FY2024, Agios Pharmaceuticals' Research & Development is $301.3 million, which was up 1.95% from $295.5 million recorded in FY2023.
  • Over the past 5 years, Agios Pharmaceuticals' Research & Development peaked at $301.3 million during FY2024, and registered a low of $220.8 million during FY2020.
  • In the last 3 years, Agios Pharmaceuticals' Research & Development had a median value of $295.5 million in 2023 and averaged $292.2 million.
  • Data for Agios Pharmaceuticals' Research & Development shows a peak YoY increased of 16.38% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Agios Pharmaceuticals' Research & Development stood at $220.8 million in 2020, then increased by 16.38% to $257.0 million in 2021, then increased by 8.93% to $279.9 million in 2022, then increased by 5.58% to $295.5 million in 2023, then climbed by 1.95% to $301.3 million in 2024.